Neurofibromatosis and schwannomatosis

Principles of Clinical Cancer Genetics: A Handbook from the Massachusetts General Hospital

Volumn , Issue , 2010, Pages 181-193

  Smith, Miriam J ^b   Plotkin, Scott R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Caf au lait spot; Mosaicism; Neurofibroma; Neurofibromatosis; NF1; NF2; Schwannoma; Schwannomatosis

Indexed keywords

EID: 84872357691     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-93846-2_13     Document Type: Chapter

References (111)

1. Lammert M, Friedman JM, Kluwe L, Mautner VF (2005) Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol 141(1):71-74
2. NIH Consensus Conference (1988) Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45(5):575-578
3. Gutmann DH, Aylsworth A, Carey JC et al (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278(1):51-57
4. DeBella K, Szudek J, Friedman JM (2000) Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 105(3 Pt 1):608-614
5. Leonard JR, Perry A, Rubin JB, King AA, Chicoine MR, Gutmann DH (2006) The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology 67(8):1509-1512
6. Huson SM, Harper PS, Compston DA (1988) Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 111(Pt 6):1355-1381
7. Waggoner DJ, Towbin J, Gottesman G, Gutmann DH (2000) Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. Am J Med Genet 92(2):132-135
8. Friedman JM, Birch PH (1997) Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1, 728 patients. Am J Med Genet 70(2):138-143
9. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39(5):311-314
10. McCaughan JA, Holloway SM, Davidson R, Lam WW (2007) Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1. J Med Genet 44(7):463-466
11. Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM (2005) Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 65(2):205-211
12. Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26(1):93-97
13. Gutmann DH, Rasmussen SA, Wolkenstein P et al (2002) Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology 59(5):759-761
14. Guillamo JS, Creange A, Kalifa C et al (2003) Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 126(Pt 1):152-160
15. Miyata S, Sugimoto T, Kodama T et al (2005) Adenoid glioblastoma arising in a patient with neurofibromatosis type-1. Pathol Int 55(6):348-352
16. North K, Hyman S, Barton B (2002) Cognitive deficits in neurofibromatosis 1. J Child Neurol 17(8):605-612
17. Creange A, Zeller J, Rostaing-Rigattieri S et al (1999) Neurological complications of neurofibromatosis type 1 in adulthood. Brain 122(Pt 3):473-481
18. Li Y, O'Connell P, Breidenbach HH et al (1995) Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics 25(1):9-18
19. Messiaen LM, Callens T, Mortier G et al (2000) Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 15(6):541-555
20. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF (2002) Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296(5569):920-922
21. Serra E, Rosenbaum T, Winner U et al (2000) Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum Mol Genet 9(20):3055-3064
22. De SS, Maertens O, Callens T, Naeyaert JM, Lambert J, Messiaen L (2008) Somatic mutation analysis in NF1 cafe au lait spots reveals two NF1 hits in the melanocytes. J Invest Dermatol 128(4): 1050-1053
23. Cnossen MH, van der Est MN, Breuning MH et al (1997) Deletions spanning the neurofibromatosis type 1 gene: implications for genotype- phenotype correlations in neurofibromatosis type 1? Hum Mutat 9(5):458-464
24. Kehrer-Sawatzki H, Kluwe L, Funsterer C, Mautner VF (2005) Extensively high load of internal tumors determined by whole body MRI scanning in a patient with neurofibromatosis type 1 and a non-LCR-mediated 2-Mb deletion in 17q11.2. Hum Genet 116(6):466-475
25. Upadhyaya M, Huson SM, Davies M et al (2007) An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet 80(1):140-151
26. Maertens O, De SS, Vandesompele J et al (2007) Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1. Am J Hum Genet 81(2):243-251
27. Ruggieri M, Huson SM (2001) The clinical and diagnostic implications of mosaicism in the neurofibromatoses. Neurology 56(11): 1433-1443
28. Vandenbroucke I, Callens T, De PA, Messiaen L (2002) Complex splicing pattern generates great diversity in human NF1 transcripts. BMC Genomics 3(1):13
29. Viskochil D, Cawthon R, O'Connell P et al (1991) The gene encoding the oligodendrocyte-myelin glycoprotein is embedded within the neurofibromatosis type 1 gene. Mol Cell Biol 11(2): 906-912
30. Serra E, Puig S, Otero D et al (1997) Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am J Hum Genet 61(3):512-519
31. Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH (2005) Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 65(7):2755-2760
32. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K (2005) The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 102(24):8573-8578
33. Dasgupta B, Li W, Perry A, Gutmann DH (2005) Glioma formation in neurofibromatosis 1 reflects preferential activation of K-Ras in astrocytes. Cancer Res 65(1):236-245
34. Spits C, De RM, Van RN et al (2005) Preimplantation genetic diagnosis for neurofibromatosis type 1. Mol Hum Reprod 11(5):381-387
35. Ferner RE, Lucas JD, O'Doherty MJ et al (2000) Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatr 68(3):353-357
36. Bredella MA, Torriani M, Hornicek F et al (2007) Value of PET in the assessment of patients with neurofibromatosis type 1. AJR Am J Roentgenol 189(4):928-935
37. Sharif S, Ferner R, Birch JM et al (2006) Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 24(16):2570-2575
38. Colman SD, Williams CA, Wallace MR (1995) Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet 11(1):90-92
39. Storlazzi CT, Von Steyern FV, Domanski HA, Mandahl N, Mertens F (2005) Biallelic somatic inactivation of the NF1 gene through chromosomal translocations in a sporadic neurofibroma. Int J Cancer 117(6):1055-1057
40. Bader JL, Miller RW (1978) Neurofibromatosis and childhood leukemia. J Pediatr 92(6):925-929
41. Kalra R, Paderanga DC, Olson K, Shannon KM (1994) Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21Ras. Blood 84(10):3435-3439
42. Bausch B, Borozdin W, Mautner VF et al (2007) Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 92(7):2784-2792
43. Opocher G, Conton P, Schiavi F, Macino B, Mantero F (2005) Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1. Fam Cancer 4(1):13-16
44. Neumann HP, Bausch B, McWhinney SR et al (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346(19):1459-1466
45. Chateil JF, Soussotte C, Pedespan JM, Brun M, Le MC, Diard F (2001) MRI and clinical differences between optic pathway tumours in children with and without neurofibromatosis. Br J Radiol 74(877):24-31
46. Warrington NM, Woerner BM, Daginakatte GC et al (2007) Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res 67(18):8588-8595
47. Gutmann DH, Hedrick NM, Li J, Nagarajan R, Perry A, Watson MA (2002) Comparative gene expression profile analysis of neurofibromatosis 1-associated and sporadic pilocytic astrocytomas. Cancer Res 62(7):2085-2091
48. Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350):577-580
49. Heinrich MC, Corless CL, Duensing A et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299(5607):708-710
50. Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440):1127-1134
51. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329-1338
52. Stewart DR, Corless CL, Rubin BP et al (2007) Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neurofibromatosis type 1. J Med Genet 44(1):e61
53. Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P (2008) Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res 14(14):4550-4555
54. Doorn PF, Molenaar WM, Buter J, Hoekstra HJ (1995) Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. Eur J Surg Oncol 21(1):78-82
55. Carli M, Ferrari A, Mattke A et al (2005) Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol 23(33):8422-8430
56. Johansson G, Mahller YY, Collins MH et al (2008) Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther 7(5): 1237-1245
57. Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R (1990) NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 113(1):39-52
58. Mautner VF, Tatagiba M, Lindenau M et al (1995) Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. AJR Am J Roentgenol 165(4): 951-955
59. Patronas NJ, Courcoutsakis N, Bromley CM, Katzman GL, MacCollin M, Parry DM (2001) Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology 218(2):434-442
60. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N (1994) Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52(4):450-461
61. Ragge NK, Baser ME, Klein J et al (1995) Ocular abnormalities in neurofibromatosis 2. Am J Ophthalmol 120(5):634-641
62. Evans DG, Huson SM, Donnai D et al (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29(12):841-846
63. Sperfeld AD, Hein C, Schroder JM, Ludolph AC, Hanemann CO (2002) Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain 125(5):996-1004
64. Hanemann CO, Diebold R, Kaufmann D (2007) Role of NF2 haploinsufficiency in NF2-associated polyneuropathy. Brain Pathol 17(4):371-376
65. Trivedi R, Byrne J, Huson SM, Donaghy M (2000) Focal amyotrophy in neurofibromatosis 2. J Neurol Neurosurg Psychiatr 69(2): 257-261
66. Rouleau GA, Wertelecki W, Haines JL et al (1987) Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 329(6136):246-248
67. Wertelecki W, Rouleau GA, Superneau DW et al (1988) Neurofibromatosis 2: clinical and DNA linkage studies of a large kindred. N Engl J Med 319(5):278-283
68. Trofatter JA, MacCollin MM, Rutter JL et al (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 75(4):826
69. Rouleau GA, Merel P, Lutchman M et al (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363(6429):515-521
70. McClatchey AI, Giovannini M (2005) Membrane organization and tumorigenesis - the NF2 tumor suppressor, Merlin. Genes Dev 19(19):2265-2277
71. Ahronowitz I, Xin W, Kiely R, Sims K, MacCollin M, Nunes FP (2007) Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Hum Mutat 28(1):1-12
72. Baser ME (2006) The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum Mutat 27(4): 297-306
73. MacCollin M, Braverman N, Viskochil D et al (1996) A point mutation associated with a severe phenotype of neurofibromatosis 2. Ann Neurol 40(3):440-445
74. Ruttledge MH, Andermann AA, Phelan CM et al (1996) Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 59(2): 331-342
75. Jacoby LB, MacCollin M, Barone R, Ramesh V, Gusella JF (1996) Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosomes Cancer 17(1):45-55
76. Wellenreuther R, Kraus JA, Lenartz D et al (1995) Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 146(4):827-832
77. Aghi M, Kluwe L, Webster MT et al (2006) Unilateral vestibular schwannoma with other neurofibromatosis Type 2-related tumors: clinical and molecular study of a unique phenotype. J Neurosurg 104:201-207
78. Kluwe L, Mautner V, Heinrich B et al (2003) Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 40(2):109-114
79. Wallace AJ, Watson CJ, Oward E, Evans DG, Elles RG (2004) Mutation scanning of the NF2 gene: an improved service based on meta-PCR/sequencing, dosage analysis, and loss of heterozygosity analysis. Genet Test 8(4):368-380
80. Evans DG, Ramsden RT, Shenton A et al (2007) Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet 44(7):424-428
81. Kluwe L, Friedrich RE, Tatagiba M, Mautner VF (2002) Presymptomatic diagnosis for children of sporadic neurofibromatosis 2 patients: a method based on tumor analysis. Genet Med 4(1):27-30
82. Liu R, Fagan P (2001) Facial nerve schwannoma: surgical excision versus conservative management. Ann Otol Rhinol Laryngol 110(11):1025-1029
83. Fuss M, Debus J, Lohr F et al (2000) Conventionally fractionated stereotactic radiotherapy (FSRT) for acoustic neuromas. Int J Radiat Oncol Biol Phys 48(5):1381-1387
84. Combs SE, Volk S, Schulz-Ertner D, Huber PE, Thilmann C, Debus J (2005) Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): long-term results in 106 patients treated in a single institution. Int J Radiat Oncol Biol Phys 63(1):75-81
85. Slattery WH III, Brackmann DE (1995) Results of surgery following stereotactic irradiation for acoustic neuromas. Am J Otol 16(3): 315-319
86. Baser ME, Evans DG, Jackler RK, Sujansky E, Rubenstein A (2000) Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer 82(4):998
87. Thomsen J, Mirz F, Wetke R, Astrup J, Bojsen-Moller M, Nielsen E (2000) Intracranial sarcoma in a patient with neurofibromatosis type 2 treated with gamma knife radiosurgery for vestibular schwannoma. Am J Otol 21(3):364-370
88. Plotkin SR, Singh MA, O'Donnell CC, Harris GJ, McClatchey AI, Halpin C (2008) Audiologic and radiographic response of NF2- related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol 5(8):487-491
89. CBTRUS (2005) Statistical report: primary brain tumors in the United States, 1998-2002
90. Welling DB, Guida M, Goll F et al (1996) Mutational spectrum in the neurofibromatosis type 2 gene in sporadic and familial schwannomas. Hum Genet 98(2):189-193
91. Nunes F, Shen Y, Niida Y et al (2005) Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma. Cancer Genet Cytogenet 162(2):135-139
92. von Haken MS, White EC, Neshvar-Shyesther L et al (1996) Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas. Genes Chromosomes Cancer 17(1):37-44
93. Ammerlaan AC, De BC, Ararou A et al (2005) Localization of a putative low-penetrance ependymoma susceptibility locus to 22q11 using a chromosome 22 tiling-path genomic microarray. Genes Chromosomes Cancer 43(4):329-338
94. Hulsebos TJ, Oskam NT, Bijleveld EH et al (1999) Evidence for an ependymoma tumour suppressor gene in chromosome region 22pter-22q11.2. Br J Cancer 81(7):1150-1154
95. Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley- Bosco E (2009) Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 64(2):140-147
96. Jongsma J, van ME, Vooijs M et al (2008) A conditional mouse model for malignant mesothelioma. Cancer Cell 13(3):261-271
97. Antinheimo J, Sankila R, Carpen O, Pukkala E, Sainio M, Jaaskelainen J (2000) Population-based analysis of sporadic and type 2 neurofibromatosis- associated meningiomas and sch wannomas. Neurology 54(1):71
98. MacCollin M, Chiocca EA, Evans DG et al (2005) Diagnostic criteria for schwannomatosis. Neurology 64(11):1838-1845
99. Jacoby LB, Jones D, Davis K et al (1997) Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet 61(6):1293-1302
100. MacCollin M, Willett C, Heinrich B et al (2003) Familial schwannomatosis: exclusion of the NF2 locus as the germline event. Neurology 60(12):1968-1974
101. Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P (2007) Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet 80(4):805-810
102. Roberts CW, Orkin SH (2004) The SWI/SNF complex-chromatin and cancer. Nat Rev Cancer 4(2):133-142
103. Sestini R, Bacci C, Provenzano A, Genuardi M, Papi L (2008) Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas. Hum Mutat 29(2): 227-231
104. Hadfield KD, Newman WG, Bowers NL et al (2008) Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet 45(6):332-339
105. Boyd C, Smith MJ, Kluwe L, Balogh A, MacCollin M, Plotkin SR (2008) Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis. Clin Genet 74(4):358-366
106. Patil S, Perry A, MacCollin M et al (2008) Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. Brain Pathol 18(4):517-519
107. Rieske P, Zakrzewska M, Piaskowski S et al (2003) Molecular heterogeneity of meningioma with INI1 mutation. Mol Pathol 56(5):299-301
108. Schmitz U, Mueller W, Weber M, Sevenet N, Delattre O, von DA (2001) INI1 mutations in meningiomas at a potential hotspot in exon 9. Br J Cancer 84(2):199-201
109. Versteege I, Sevenet N, Lange J et al (1998) Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394(6689): 203-206
110. Swensen JJ, Keyser J, Coffin CM, Biegel JA, Viskochil DH, Williams MS (2009) Familial occurrence of schwannomas and malignant rhabdoid tumour associated with a duplication in SMARCB1. J Med Genet 46(1):68-72
111. Janson K, Nedzi LA, David O et al (2006) Predisposition to atypical teratoid/rhabdoid tumor due to an inherited INI1 mutation. Pediatr Blood Cancer 47(3):279-284